Akebia Therapeutics Showcases Research at Kidney Foundation Event

Akebia Therapeutics Showcases Research at Kidney Foundation Event

Akebia Therapeutics, Inc. (NASDAQ: AKBA), a leading biopharmaceutical company dedicated to transforming the lives of individuals affected by kidney disease, is gearing up to present key findings at the National Kidney Foundation Spring Clinical Meetings 2025 (NKF SCM25). This significant event is scheduled to take place in Boston, Massachusetts, from April 10 to April 13, 2025.

Insights from the Presentations

During the NKF SCM25, Akebia will display several insightful posters that highlight their latest research efforts in the realm of chronic kidney disease. These presentations will be featured during the Exhibit Hall hours, providing an invaluable opportunity for attendees to engage with the cutting-edge work being done in this field.

Key Posters to Be Featured

One of the notable presentations will address the Cardiovascular Risk in Patients With Dialysis-Dependent Chronic Kidney Disease (DD-CKD). This study compares the efficacy of Vadadustat versus Darbepoetin Alfa in patients, with or without existing cardiovascular conditions. The findings promise to add crucial insights into treatment options for this patient population.

In addition, Akebia will present a poster examining the Treatment of Anemia in Different Age Groups. This research focuses on the effectiveness of Vadadustat for treating anemia in older versus younger patients receiving dialysis for DD-CKD. It aims to address how age may influence treatment outcomes, a vital consideration for optimizing patient care.

Oral Presentation by Dr. Wolfgang Winkelmayer

Highlighting the event, Dr. Wolfgang Winkelmayer will deliver an oral presentation on April 10, at 4:00 PM. He will discuss the findings from the poster titled “Vadadustat for Treatment of Anemia in Older vs Younger Patients With Dialysis-Dependent CKD.” This presentation promises to offer deeper insights into the implications of their research on treatment practices.

Visit Akebia at Booth #1121

Attendees of the NKF SCM25 are encouraged to visit Akebia at Booth #1121 in the Exhibit Hall. The team will be available to discuss their innovative therapies and engage in meaningful conversations about the future of kidney disease treatments.

About Akebia Therapeutics

Founded in 2007 and headquartered in Cambridge, Massachusetts, Akebia Therapeutics is a fully integrated biopharmaceutical company with a mission to enhance the quality of life for patients struggling with kidney disease. The organization prides itself on its commitment to innovation and excellence in addressing health issues that affect various patient demographics.

Contact Akebia Therapeutics

For more information, individuals can reach out to:
Mercedes Carrasco
Email: mcarrasco@akebia.com

Frequently Asked Questions

What is the purpose of Akebia's research at NKF SCM25?

Akebia aims to present its innovative therapies and research findings to enhance the understanding and treatment of kidney diseases through evidence-based approaches.

Where is the NKF Spring Clinical Meetings 2025 being held?

The meetings will take place in Boston, Massachusetts, attracting healthcare professionals and researchers from across the field of nephrology.

What topics will be covered by Akebia at the event?

Akebia will discuss cardiovascular risks in CKD patients and treatment strategies for anemia in different age groups receiving dialysis.

Who will be presenting at the event?

Dr. Wolfgang Winkelmayer will present a key oral presentation regarding the efficacy of Vadadustat in treating anemia among dialysis-dependent CKD patients.

How can I learn more about Akebia Therapeutics?

Visit Akebia's official website at www.akebia.com for comprehensive information on their research, products, and corporate initiatives.

About The Author

Olivia Taylor here, a 26-year-old writer and financial advisor. After earning a degree in finance, I worked in the sector for years. I've always loved numbers and had a talent for simplifying difficult financial ideas so that anyone could understand. I wrote my first book because of this passion; it helps readers take charge of their financial futures by fusing real-life stories with useful financial advice.

Whether they are just beginning their careers, preparing for significant life events, or seeking to invest wisely, my goal with my writing is to enable people to make educated financial decisions. The foundation of my work is the conviction that security and freedom of the individual are largely determined by financial literacy. To further financial education, I run workshops and frequently write for financial blogs in addition to my books.

I like to travel, experience other cultures, and find inspiration in daily life when I'm not writing or examining market trends. My passion is utilizing sound financial practices to help people reach their financial objectives and lead the best lives possible.

Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.